Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer

Overview of attention for article published in Cochrane database of systematic reviews, May 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 22 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 93 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 26 X posts from 22 X users, with an upper bound of 190,611 followers.

@drlw2309 This updated meta-analysis shows OS benefit of capecitabine in TNBC in the adjuvant setting - so it can no longer be an excuse to give neoadjuvant chemotherapy; in fact the latter may deny it to patients in whom it might be beneficial. https://

18 Oct 2021

Reply Repost Favourite

RT @jsvaidya: @SirohiBhawna @oncology_bg @ajumathew_ @sujithonco @DrSanjayPopat @JyotiBajpai01 @GillSharlene @weoncologists @oncologician @…

01 Oct 2021

Reply Repost Favourite

RT @ajumathew_: One advantage of neoadj chemo is illustrated in this vignette from my practice. I now know she has a rather chemo resista…

01 Oct 2021

Reply Repost Favourite

RT @jsvaidya: @SirohiBhawna @oncology_bg @ajumathew_ @sujithonco @DrSanjayPopat @JyotiBajpai01 @GillSharlene @weoncologists @oncologician @…

01 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 22 additional X posts.